Janssen presents latest real-world data at the ASCO 2016 Congress
The Janssen EMEA team was excited to present interim analysis data from The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration-resistant prostate cancer (mCRPC), at the American Society of Clinical Oncology (ASCO) 2016 Congress over the weekend.
The data revealed insights into how the presence of metastases at initial prostate cancer diagnosis may have a critical impact on prognosis for mCRPC patients.
Jane Griffiths, Company Group Chairman, Janssen EMEA said: “Janssen is proud to be supporting The Prostate Cancer Registry, which is the largest of its kind in Europe. As there is currently limited data available on the everyday experience of mCRPC patients we hope that the insights from the trial will lead to an improvement in the quality of care and prognosis for men with mCRPC.”
The Prostate Cancer Registry was initiated in 2013 and has enrolled over 3,000 mCRPC patients in 199 centres across 16 European countries. This breakthrough study aims to address key medical and scientific questions concerning the optimal care of mCRPC patients in routine practice, looking at a wider patient population to complement clinical trials.
Congratulations to all those who have worked hard on the study so far and we very much look forward to seeing more results over the next few years!
Key facts on mCRPC:
- mCRPC occurs when cancer has spread beyond the prostate to other parts of the body and the disease progresses despite serum testosterone below castrate levels.
- In 2012, over 400,000 new cases of prostate cancer were diagnosed in Europe, and nearly 92,000 men died from the disease.